Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
26 September 2023 - 10:30PM
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS
("bYoRNA") today announced that they entered into a development and
commercialization agreement to work on disruptive bioproduction
technologies that will help exploit the therapeutic potential of
messenger RNA ("mRNA"). Dyadic is a global biotechnology company
focused on building innovative microbial platforms to address the
growing demand for global protein bioproduction and unmet clinical
needs for effective, affordable, and accessible biopharmaceutical
products and alternative proteins for human and animal health.
bYoRNA is a French biotechnology company focused on producing
affordable therapeutic mRNA, at scale, for human and animal health.
“I am excited to announce this development and
commercialization agreement to explore the potential to utilize our
C1 protein production platform to produce high-quality messenger
RNA products at lower cost which will be easier to manufacture than
in vitro mRNA, making it accessible to everyone, including patients
from poorer countries. The global mRNA vaccine and therapeutics
market was valued at USD 34.7 billion in 2022 and is expected to
reach USD 68.1 billion by 2030, making this an extremely valuable
potential opportunity for both companies to enter the rapidly
expanding market for mRNA-based vaccines and therapies, said Mark
Emalfarb, Dyadic’s Chief Executive Officer. “If this collaboration
is successful, Dyadic has the potential to receive certain defined
milestone and royalty payments from bYoRNA and the ability to
obtain a license to the BRNA platform,” Mr. Emalfarb concluded.
“The COVID-19 pandemic brought mRNA technology
to the forefront, showing its potential to prevent and treat
diseases. Within this collaboration, we will combine our respective
technologies to try to express "bio" RNA from Dyadic's eukaryotic
C1-cells, to design, develop and commercialize messenger RNA
products,” said Pascal Viguié, bYoRNA's Chief Executive
Officer.
“We believe that by combining bYoRNA’s novel
eukaryotic "bio" RNA platform with Dyadic’s industrially proven C1
protein production platform, we will be able to provide the
pharmaceutical industry with a more cost-efficient platform for
manufacturing large quantities of lower cost mRNA, enabling access
to mRNA vaccines and drugs to a broader global population,” said
Thierry Ziegler, bYoRNA’s Chief Technology Officer.
About bYoRNA
SAS
bYoRNA SAS is a French biotechnology company
focused on developing a cost-efficient and scalable mRNA
bioproduction platform for prophylactic and oncological vaccines.
mRNA is currently produced in vitro via enzymatic synthesis, an
expensive method. Our bioproduction technology will help mass
produce long, GMP-grade mRNA in a cost-efficient and scalable
fashion by leveraging processes in engineered living cells.
By bringing down the production cost of mRNA and
simplifying the supply chain to make it local and more resilient,
bYoRNA will help make mRNA vaccines available to the population of
emerging countries. By producing longer, naturally modified mRNA,
bYoRNA will contribute to the emergence of novel mRNA-based
modalities.
To learn more about bYoRNA and its commitment to
helping produce mRNA vaccines in greater volumes and at lower cost,
please visit https://www.byorna.bio.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company focused on building innovative microbial
platforms to address the growing demand for global protein
bioproduction and unmet clinical needs for effective, affordable,
and accessible biopharmaceutical products and alternative proteins
for human and animal health.
Dyadic’s gene expression and protein production
platforms are based on the highly productive and scalable
fungus Thermothelomyces heterothallica (formerly
Myceliophthora thermophila). Our lead technology, C1-cell
protein production platform, is based on an industrially proven
microorganism (named C1), which is currently used to speed
development, lower production costs, and improve performance of
biologic vaccines and drugs at flexible commercial scales for the
human and animal health markets. Dyadic has also developed the
Dapibus™ filamentous fungal based microbial protein production
platform to enable the rapid development and large-scale
manufacture of low-cost proteins, metabolites, and other biologic
products for use in non-pharmaceutical applications, such as food,
nutrition, and wellness.
With a passion to enable our partners and
collaborators to develop effective preventative and therapeutic
treatments in both developed and emerging countries, Dyadic is
building an active pipeline by advancing its proprietary microbial
platform technologies, including our lead asset DYAI-100 COVID-19
vaccine candidate, as well as other biologic vaccines, antibodies,
and other biological products.
To learn more about Dyadic and our commitment to
helping bring vaccines and other biologic products to market
faster, in greater volumes and at lower cost, please
visit https://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
including those regarding Dyadic International’s expectations,
intentions, strategies, and beliefs pertaining to future events or
future financial performance, such as the success of our clinical
trial and interest in our protein production platforms, our
research projects and third-party collaborations, as well as the
availability of necessary funding. Actual events or results may
differ materially from those in the forward-looking statements
because of various important factors, including those described in
the Company’s most recent filings with the SEC. Dyadic assumes no
obligation to update publicly any such forward-looking statements,
whether because of new information, future events or otherwise. For
a more complete description of the risks that could cause our
actual results to differ from our current expectations, please see
the section entitled “Risk Factors” in Dyadic’s annual reports on
Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as
such factors may be updated from time to time in Dyadic’s periodic
filings with the SEC, which are accessible on the SEC’s website and
at www.dyadic.com.
Contact Dyadic: |
Contact bYoRNA: |
Dyadic International, Inc. |
bYoRNA SAS |
Ping W. Rawson |
Pascal Viguié |
Chief Financial Officer |
Chief Executive Officer |
Phone: (561) 743-8333 |
Email: pr@byorna.bio |
Email: ir@dyadic.com |
|
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2024 to May 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From May 2023 to May 2024